In summary, the results of this study indicate that CUL4B promotes TMZ resistance in GBM cells by epigenetically repressing CDKN1A transcription, CUL4B is a significant clinical prognostic factor and may serve as a promising therapeutic target for the treatment of gliomas. Here, CUL4B is linked to glioblastoma.